Trial Outcomes & Findings for Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors (NCT NCT01803282)

NCT ID: NCT01803282

Last Updated: 2020-06-02

Results Overview

• Recruitment status: COMPLETED
• Study phase: PHASE1
• Target enrollment: 236 participants
• Primary outcome timeframe: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days
• Results posted on: 2020-06-02

Participant Flow

Participants were enrolled at study sites in the United States. The first participant was screened on 29 March 2013. The last study visit occurred on 23 April 2019.

280 participants were screened.

Participant milestones

Measure	Part A: ADX 200 mg Participants with advanced solid tumors who had failed or were intolerant to standard therapy or for whom no standard therapy existed, received 200 mg andecaliximab (ADX) as monotherapy via intravenous (IV) infusion (approximately 30 minutes) every 2 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part A: ADX 600 mg Participants with advanced solid tumors who had failed or were intolerant to standard therapy or for whom no standard therapy existed, received 600 mg ADX as monotherapy via IV infusion (approximately 30 minutes) every 2 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part A: ADX 1800 mg Participants with advanced solid tumors who had failed or were intolerant to standard therapy or for whom no standard therapy existed, received 1800 mg ADX as monotherapy via IV infusion (approximately 30 minutes) every 2 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: PAC, ADX 800 mg Participants with pancreatic adenocarcinoma (PAC) received ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (gemcitabine and nab paclitaxel, on Days 1, 8, and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: LAC, ADX 1200 mg Participants with lung adenocarcinoma (LAC) received ADX 1200 mg every 3 weeks via IV infusion in addition to the 21-day cycle chemotherapy (carboplatin and pemetrexed, on Day 1) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: LSC, ADX 1200 mg Participants with lung squamous cell carcinoma (LSC) received ADX 1200 mg every 3 weeks via IV infusion in addition to the 21-day cycle chemotherapy (carboplatin and paclitaxel, on Day 1) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: EGC, ADX 800 mg Participants with esophagogastric adenocarcinoma (EGC) received ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (leucovorin+oxaliplatin+5-fluorouracil {5-FU} \[mFOLFOX6\], on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: FL CRC, ADX 800 mg+BEV 5 mg/kg Participants with colorectal cancer (CRC) received first-line (FL) treatment with ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (mFOLFOX6 and bevacizumab 5 mg/kg, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: FL CRC, ADX 800 mg+BEV 10 mg/kg Participants with CRC received FL treatment with ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (mFOLFOX6 and bevacizumab 10 mg/kg, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: SL CRC, ADX 800 mg+BEV 5 mg/kg Participants with CRC received second-line (SL) treatment with ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (leucovorin+irinotecan+5-FU \[FOLFIRI\] and bevacizumab 5 mg/kg, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: SL CRC, ADX 800 mg+BEV 10 mg/kg Participants with CRC received SL treatment with ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (FOLFIRI and bevacizumab 10 mg/kg, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: BRCA, ADX 800 mg Participants with breast cancer (BRCA) received ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (paclitaxel, on Days 1, 8, and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
Overall Study STARTED	4	3	6	36	11	10	41	46	11	45	8	15
Overall Study COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0
Overall Study NOT COMPLETED	4	3	6	36	11	10	41	46	11	45	8	15

Reasons for withdrawal

Measure	Part A: ADX 200 mg Participants with advanced solid tumors who had failed or were intolerant to standard therapy or for whom no standard therapy existed, received 200 mg andecaliximab (ADX) as monotherapy via intravenous (IV) infusion (approximately 30 minutes) every 2 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part A: ADX 600 mg Participants with advanced solid tumors who had failed or were intolerant to standard therapy or for whom no standard therapy existed, received 600 mg ADX as monotherapy via IV infusion (approximately 30 minutes) every 2 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part A: ADX 1800 mg Participants with advanced solid tumors who had failed or were intolerant to standard therapy or for whom no standard therapy existed, received 1800 mg ADX as monotherapy via IV infusion (approximately 30 minutes) every 2 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: PAC, ADX 800 mg Participants with pancreatic adenocarcinoma (PAC) received ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (gemcitabine and nab paclitaxel, on Days 1, 8, and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: LAC, ADX 1200 mg Participants with lung adenocarcinoma (LAC) received ADX 1200 mg every 3 weeks via IV infusion in addition to the 21-day cycle chemotherapy (carboplatin and pemetrexed, on Day 1) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: LSC, ADX 1200 mg Participants with lung squamous cell carcinoma (LSC) received ADX 1200 mg every 3 weeks via IV infusion in addition to the 21-day cycle chemotherapy (carboplatin and paclitaxel, on Day 1) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: EGC, ADX 800 mg Participants with esophagogastric adenocarcinoma (EGC) received ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (leucovorin+oxaliplatin+5-fluorouracil {5-FU} \[mFOLFOX6\], on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: FL CRC, ADX 800 mg+BEV 5 mg/kg Participants with colorectal cancer (CRC) received first-line (FL) treatment with ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (mFOLFOX6 and bevacizumab 5 mg/kg, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: FL CRC, ADX 800 mg+BEV 10 mg/kg Participants with CRC received FL treatment with ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (mFOLFOX6 and bevacizumab 10 mg/kg, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: SL CRC, ADX 800 mg+BEV 5 mg/kg Participants with CRC received second-line (SL) treatment with ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (leucovorin+irinotecan+5-FU \[FOLFIRI\] and bevacizumab 5 mg/kg, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: SL CRC, ADX 800 mg+BEV 10 mg/kg Participants with CRC received SL treatment with ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (FOLFIRI and bevacizumab 10 mg/kg, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: BRCA, ADX 800 mg Participants with breast cancer (BRCA) received ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (paclitaxel, on Days 1, 8, and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
Overall Study Progressive Disease	4	3	6	22	5	8	23	24	3	29	6	11
Overall Study Death	0	0	0	0	2	1	1	5	1	1	0	0
Overall Study Withdrew Consent	0	0	0	6	1	0	8	3	1	5	0	1
Overall Study Investigator's Discretion	0	0	0	7	2	1	7	10	6	7	1	0
Overall Study Adverse Event	0	0	0	0	0	0	1	2	0	1	0	3
Overall Study Non-Compliance with Study Drug	0	0	0	1	0	0	0	0	0	0	0	0
Overall Study Unknown Reason	0	0	0	0	0	0	0	1	0	0	0	0
Overall Study Specified Criteria for Withdrawal	0	0	0	0	0	0	0	0	0	1	1	0
Overall Study Enrolled but Never Treated	0	0	0	0	1	0	1	1	0	1	0	0

Baseline Characteristics

Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors

Baseline characteristics by cohort

Measure	Part A: ADX 200 mg n=4 Participants Participants with advanced solid tumors who had failed or were intolerant to standard therapy or for whom no standard therapy existed, received 200 mg ADX as monotherapy via IV infusion (approximately 30 minutes) every 2 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part A: ADX 600 mg n=3 Participants Participants with advanced solid tumors who had failed or were intolerant to standard therapy or for whom no standard therapy existed, received 600 mg ADX as monotherapy via IV infusion (approximately 30 minutes) every 2 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part A: ADX 1800 mg n=6 Participants Participants with advanced solid tumors who had failed or were intolerant to standard therapy or for whom no standard therapy existed, received 1800 mg ADX as monotherapy via IV infusion (approximately 30 minutes) every 2 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: PAC, ADX 800 mg n=36 Participants Participants with PAC received ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (gemcitabine and nab paclitaxel, on Days 1, 8, and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: LAC, ADX 1200 mg n=10 Participants Participants with LAC received ADX 1200 mg every 3 weeks via IV infusion in addition to the 21-day cycle chemotherapy (carboplatin and pemetrexed, on Day 1) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: LSC, ADX 1200 mg n=10 Participants Participants with LSC received ADX 1200 mg every 3 weeks via IV infusion in addition to the 21-day cycle chemotherapy (carboplatin and paclitaxel, on Day 1) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: EGC, ADX 800 mg n=40 Participants Participants with EGC received ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (mFOLFOX6, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: FL CRC, ADX 800 mg+BEV 5 mg/kg n=45 Participants Participants with CRC received FL treatment with ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (mFOLFOX6 and bevacizumab 5 mg/kg, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: FL CRC, ADX 800 mg+BEV 10 mg/kg n=11 Participants Participants with CRC received FL treatment with ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (mFOLFOX6 and bevacizumab 10 mg/kg, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: SL CRC, ADX 800 mg+BEV 5 mg/kg n=44 Participants Participants with CRC received SL treatment with ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (FOLFIRI and bevacizumab 5 mg/kg, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: SL CRC, ADX 800 mg+BEV 10 mg/kg n=8 Participants Participants with CRC received SL treatment with ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (FOLFIRI and bevacizumab 10 mg/kg, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: BRCA, ADX 800 mg n=15 Participants Participants with BRCA received ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (paclitaxel, on Days 1, 8, and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Total n=232 Participants Total of all reporting groups
Age, Customized Age · < 65 years	2 Participants n=5 Participants	0 Participants n=7 Participants	4 Participants n=5 Participants	15 Participants n=4 Participants	2 Participants n=21 Participants	4 Participants n=8 Participants	25 Participants n=8 Participants	26 Participants n=24 Participants	8 Participants n=42 Participants	33 Participants n=42 Participants	4 Participants n=42 Participants	10 Participants n=42 Participants	133 Participants n=36 Participants
Age, Customized Age · ≥ 65 years	2 Participants n=5 Participants	3 Participants n=7 Participants	2 Participants n=5 Participants	21 Participants n=4 Participants	8 Participants n=21 Participants	6 Participants n=8 Participants	15 Participants n=8 Participants	19 Participants n=24 Participants	3 Participants n=42 Participants	11 Participants n=42 Participants	4 Participants n=42 Participants	5 Participants n=42 Participants	99 Participants n=36 Participants
Sex: Female, Male Female	1 Participants n=5 Participants	0 Participants n=7 Participants	2 Participants n=5 Participants	10 Participants n=4 Participants	7 Participants n=21 Participants	4 Participants n=8 Participants	9 Participants n=8 Participants	19 Participants n=24 Participants	3 Participants n=42 Participants	25 Participants n=42 Participants	2 Participants n=42 Participants	13 Participants n=42 Participants	95 Participants n=36 Participants
Sex: Female, Male Male	3 Participants n=5 Participants	3 Participants n=7 Participants	4 Participants n=5 Participants	26 Participants n=4 Participants	3 Participants n=21 Participants	6 Participants n=8 Participants	31 Participants n=8 Participants	26 Participants n=24 Participants	8 Participants n=42 Participants	19 Participants n=42 Participants	6 Participants n=42 Participants	2 Participants n=42 Participants	137 Participants n=36 Participants
Race/Ethnicity, Customized Ethnicity · Hispanic or Latino	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	4 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=8 Participants	4 Participants n=8 Participants	4 Participants n=24 Participants	0 Participants n=42 Participants	4 Participants n=42 Participants	0 Participants n=42 Participants	2 Participants n=42 Participants	19 Participants n=36 Participants
Race/Ethnicity, Customized Ethnicity · Not Hispanic or Latino	4 Participants n=5 Participants	3 Participants n=7 Participants	6 Participants n=5 Participants	32 Participants n=4 Participants	10 Participants n=21 Participants	9 Participants n=8 Participants	30 Participants n=8 Participants	39 Participants n=24 Participants	10 Participants n=42 Participants	39 Participants n=42 Participants	8 Participants n=42 Participants	12 Participants n=42 Participants	202 Participants n=36 Participants
Race/Ethnicity, Customized Ethnicity · Not Permitted	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	6 Participants n=8 Participants	2 Participants n=24 Participants	1 Participants n=42 Participants	1 Participants n=42 Participants	0 Participants n=42 Participants	1 Participants n=42 Participants	11 Participants n=36 Participants
Race/Ethnicity, Customized Race · American Indian or Alaska Native	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	1 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	1 Participants n=8 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	1 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	3 Participants n=36 Participants
Race/Ethnicity, Customized Race · Asian	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=8 Participants	1 Participants n=8 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	2 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	4 Participants n=36 Participants
Race/Ethnicity, Customized Race · Black or African American	0 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants	3 Participants n=8 Participants	1 Participants n=8 Participants	6 Participants n=24 Participants	2 Participants n=42 Participants	2 Participants n=42 Participants	1 Participants n=42 Participants	1 Participants n=42 Participants	18 Participants n=36 Participants
Race/Ethnicity, Customized Race · Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=36 Participants
Race/Ethnicity, Customized Race · White	3 Participants n=5 Participants	3 Participants n=7 Participants	5 Participants n=5 Participants	33 Participants n=4 Participants	9 Participants n=21 Participants	5 Participants n=8 Participants	31 Participants n=8 Participants	35 Participants n=24 Participants	8 Participants n=42 Participants	35 Participants n=42 Participants	6 Participants n=42 Participants	12 Participants n=42 Participants	185 Participants n=36 Participants
Race/Ethnicity, Customized Race · Not Permitted	1 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	6 Participants n=8 Participants	3 Participants n=24 Participants	0 Participants n=42 Participants	2 Participants n=42 Participants	0 Participants n=42 Participants	1 Participants n=42 Participants	13 Participants n=36 Participants
Race/Ethnicity, Customized Race · Other	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	2 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=8 Participants	0 Participants n=8 Participants	1 Participants n=24 Participants	1 Participants n=42 Participants	2 Participants n=42 Participants	1 Participants n=42 Participants	1 Participants n=42 Participants	9 Participants n=36 Participants

PRIMARY outcome

Timeframe: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days

Population: The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).

Outcome measures

Measure	Part A: ADX 200 mg n=4 Participants Participants with advanced solid tumors who had failed or were intolerant to standard therapy or for whom no standard therapy existed, received 200 mg ADX as monotherapy via IV infusion (approximately 30 minutes) every 2 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part A: ADX 600 mg n=3 Participants Participants with advanced solid tumors who had failed or were intolerant to standard therapy or for whom no standard therapy existed, received 600 mg ADX as monotherapy via IV infusion (approximately 30 minutes) every 2 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part A: ADX 1800 mg n=6 Participants Participants with advanced solid tumors who had failed or were intolerant to standard therapy or for whom no standard therapy existed, received 1800 mg ADX as monotherapy via IV infusion (approximately 30 minutes) every 2 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: PAC, ADX 800 mg n=36 Participants Participants with PAC received ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (gemcitabine and nab paclitaxel, on Days 1, 8, and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: LAC, ADX 1200 mg n=10 Participants Participants with LAC received ADX 1200 mg every 3 weeks via IV infusion in addition to the 21-day cycle chemotherapy (carboplatin and pemetrexed, on Day 1) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: LSC, ADX 1200 mg n=10 Participants Participants with LSC received ADX 1200 mg every 3 weeks via IV infusion in addition to the 21-day cycle chemotherapy (carboplatin and paclitaxel, on Day 1) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: EGC, ADX 800 mg n=40 Participants Participants with EGC received ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (mFOLFOX6, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: FL CRC, ADX 800 mg+BEV 5 mg/kg n=45 Participants Participants with CRC received FL treatment with ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (mFOLFOX6 and bevacizumab 5 mg/kg, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: FL CRC, ADX 800 mg+BEV 10 mg/kg n=11 Participants Participants with CRC received FL treatment with ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (mFOLFOX6 and bevacizumab 10 mg/kg, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: SL CRC, ADX 800 mg+BEV 5 mg/kg n=44 Participants Participants with CRC received SL treatment with ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (FOLFIRI and bevacizumab 5 mg/kg, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: SL CRC, ADX 800 mg+BEV 10 mg/kg n=8 Participants Participants with CRC received SL treatment with ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (FOLFIRI and bevacizumab 10 mg/kg, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: BRCA, ADX 800 mg n=15 Participants Participants with BRCA received ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (paclitaxel, on Days 1, 8, and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
Percentage of Participants Experiencing Treatment-Emergent Adverse Events	100.0 percentage of participants	100.0 percentage of participants	83.3 percentage of participants	100.0 percentage of participants	100.0 percentage of participants	100.0 percentage of participants	100.0 percentage of participants	100.0 percentage of participants	100.0 percentage of participants	100.0 percentage of participants	100.0 percentage of participants	100.0 percentage of participants

PRIMARY outcome

Timeframe: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days

Population: Participants in the Safety Analysis Set were analyzed.

Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. Participants with any laboratory abnormality were reported.

Outcome measures

Measure	Part A: ADX 200 mg n=4 Participants Participants with advanced solid tumors who had failed or were intolerant to standard therapy or for whom no standard therapy existed, received 200 mg ADX as monotherapy via IV infusion (approximately 30 minutes) every 2 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part A: ADX 600 mg n=3 Participants Participants with advanced solid tumors who had failed or were intolerant to standard therapy or for whom no standard therapy existed, received 600 mg ADX as monotherapy via IV infusion (approximately 30 minutes) every 2 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part A: ADX 1800 mg n=6 Participants Participants with advanced solid tumors who had failed or were intolerant to standard therapy or for whom no standard therapy existed, received 1800 mg ADX as monotherapy via IV infusion (approximately 30 minutes) every 2 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: PAC, ADX 800 mg n=36 Participants Participants with PAC received ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (gemcitabine and nab paclitaxel, on Days 1, 8, and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: LAC, ADX 1200 mg n=10 Participants Participants with LAC received ADX 1200 mg every 3 weeks via IV infusion in addition to the 21-day cycle chemotherapy (carboplatin and pemetrexed, on Day 1) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: LSC, ADX 1200 mg n=10 Participants Participants with LSC received ADX 1200 mg every 3 weeks via IV infusion in addition to the 21-day cycle chemotherapy (carboplatin and paclitaxel, on Day 1) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: EGC, ADX 800 mg n=40 Participants Participants with EGC received ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (mFOLFOX6, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: FL CRC, ADX 800 mg+BEV 5 mg/kg n=45 Participants Participants with CRC received FL treatment with ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (mFOLFOX6 and bevacizumab 5 mg/kg, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: FL CRC, ADX 800 mg+BEV 10 mg/kg n=11 Participants Participants with CRC received FL treatment with ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (mFOLFOX6 and bevacizumab 10 mg/kg, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: SL CRC, ADX 800 mg+BEV 5 mg/kg n=44 Participants Participants with CRC received SL treatment with ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (FOLFIRI and bevacizumab 5 mg/kg, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: SL CRC, ADX 800 mg+BEV 10 mg/kg n=8 Participants Participants with CRC received SL treatment with ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (FOLFIRI and bevacizumab 10 mg/kg, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: BRCA, ADX 800 mg n=15 Participants Participants with BRCA received ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (paclitaxel, on Days 1, 8, and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
Percentage of Participants Experiencing Laboratory Abnormalities Any Laboratory abnormalities: Hematology	0.0 percentage of participants	33.3 percentage of participants	33.3 percentage of participants	97.2 percentage of participants	90.0 percentage of participants	80.0 percentage of participants	87.5 percentage of participants	84.4 percentage of participants	90.9 percentage of participants	95.5 percentage of participants	100.0 percentage of participants	86.7 percentage of participants
Percentage of Participants Experiencing Laboratory Abnormalities Any Laboratory abnormalities: Serum Chemistry	100.0 percentage of participants	66.7 percentage of participants	83.3 percentage of participants	88.9 percentage of participants	60.0 percentage of participants	70.0 percentage of participants	87.5 percentage of participants	95.6 percentage of participants	81.8 percentage of participants	86.4 percentage of participants	87.5 percentage of participants	66.7 percentage of participants
Percentage of Participants Experiencing Laboratory Abnormalities Any Laboratory abnormalities: Coagulation	25.0 percentage of participants	0.0 percentage of participants	33.3 percentage of participants	38.9 percentage of participants	10.0 percentage of participants	10.0 percentage of participants	35.0 percentage of participants	37.8 percentage of participants	36.4 percentage of participants	45.5 percentage of participants	37.5 percentage of participants	40.0 percentage of participants

Adverse Events

Part A: ADX 200 mg

Serious events: 0 serious events

Other events: 4 other events

Deaths: 1 deaths

Part A: ADX 600 mg

Serious events: 0 serious events

Other events: 3 other events

Deaths: 0 deaths

Part A: ADX 1800 mg

Serious events: 2 serious events

Other events: 5 other events

Deaths: 1 deaths

Part B: PAC, ADX 800 mg

Serious events: 19 serious events

Other events: 36 other events

Deaths: 8 deaths

Part B: LAC, ADX 1200 mg

Serious events: 5 serious events

Other events: 9 other events

Deaths: 4 deaths

Part B: LSC, ADX 1200 mg

Serious events: 6 serious events

Other events: 10 other events

Deaths: 3 deaths

Part B: EGC, ADX 800 mg

Serious events: 19 serious events

Other events: 40 other events

Deaths: 13 deaths

Part B: FL CRC, ADX 800 mg+BEV 5 mg/kg

Serious events: 17 serious events

Other events: 45 other events

Deaths: 22 deaths

Part B: FL CRC, ADX 800 mg+BEV 10 mg/kg

Serious events: 3 serious events

Other events: 11 other events

Deaths: 5 deaths

Part B: SL CRC, ADX 800 mg+BEV 5 mg/kg

Serious events: 13 serious events

Other events: 44 other events

Deaths: 25 deaths

Part B: SL CRC, ADX 800 mg+BEV 10 mg/kg

Serious events: 4 serious events

Other events: 8 other events

Deaths: 5 deaths

Part B: BRCA, ADX 800 mg

Serious events: 5 serious events

Other events: 15 other events

Deaths: 8 deaths

Serious adverse events

Measure	Part A: ADX 200 mg n=4 participants at risk Participants with advanced solid tumors who had failed or were intolerant to standard therapy or for whom no standard therapy existed, received 200 mg ADX as monotherapy via IV infusion (approximately 30 minutes) every 2 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part A: ADX 600 mg n=3 participants at risk Participants with advanced solid tumors who had failed or were intolerant to standard therapy or for whom no standard therapy existed, received 600 mg ADX as monotherapy via IV infusion (approximately 30 minutes) every 2 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part A: ADX 1800 mg n=6 participants at risk Participants with advanced solid tumors who had failed or were intolerant to standard therapy or for whom no standard therapy existed, received 1800 mg ADX as monotherapy via IV infusion (approximately 30 minutes) every 2 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: PAC, ADX 800 mg n=36 participants at risk Participants with PAC received ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (gemcitabine and nab paclitaxel, on Days 1, 8, and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: LAC, ADX 1200 mg n=10 participants at risk Participants with LAC received ADX 1200 mg every 3 weeks via IV infusion in addition to the 21-day cycle chemotherapy (carboplatin and pemetrexed, on Day 1) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: LSC, ADX 1200 mg n=10 participants at risk Participants with LSC received ADX 1200 mg every 3 weeks via IV infusion in addition to the 21-day cycle chemotherapy (carboplatin and paclitaxel, on Day 1) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: EGC, ADX 800 mg n=40 participants at risk Participants with EGC received ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (mFOLFOX6, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: FL CRC, ADX 800 mg+BEV 5 mg/kg n=45 participants at risk Participants with CRC received FL treatment with ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (mFOLFOX6 and bevacizumab 5 mg/kg, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: FL CRC, ADX 800 mg+BEV 10 mg/kg n=11 participants at risk Participants with CRC received FL treatment with ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (mFOLFOX6 and bevacizumab 10 mg/kg, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: SL CRC, ADX 800 mg+BEV 5 mg/kg n=44 participants at risk Participants with CRC received SL treatment with ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (FOLFIRI and bevacizumab 5 mg/kg, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: SL CRC, ADX 800 mg+BEV 10 mg/kg n=8 participants at risk Participants with CRC received SL treatment with ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (FOLFIRI and bevacizumab 10 mg/kg, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: BRCA, ADX 800 mg n=15 participants at risk Participants with BRCA received ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (paclitaxel, on Days 1, 8, and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
Blood and lymphatic system disorders Anaemia	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Blood and lymphatic system disorders Febrile neutropenia	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 1/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Blood and lymphatic system disorders Leukocytosis	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Blood and lymphatic system disorders Neutropenia	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Blood and lymphatic system disorders Pancytopenia	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Cardiac disorders Acute coronary syndrome	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Cardiac disorders Acute myocardial infarction	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Cardiac disorders Atrial fibrillation	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Cardiac disorders Atrial flutter	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Cardiac disorders Cardiac arrest	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Cardiac disorders Pericardial effusion	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Endocrine disorders Adrenal haemorrhage	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Eye disorders Eyelid ptosis	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Gastrointestinal disorders Abdominal discomfort	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Gastrointestinal disorders Abdominal distension	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Gastrointestinal disorders Abdominal pain	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.0% 2/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 1/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Gastrointestinal disorders Abdominal pain upper	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Gastrointestinal disorders Ascites	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.0% 2/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Gastrointestinal disorders Colitis ischaemic	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Gastrointestinal disorders Constipation	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Gastrointestinal disorders Diarrhoea	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.6% 2/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 1/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Gastrointestinal disorders Duodenal obstruction	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	16.7% 1/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Gastrointestinal disorders Duodenal perforation	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Gastrointestinal disorders Dysphagia	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Gastrointestinal disorders Enteritis	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Gastrointestinal disorders Gastric haemorrhage	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Gastrointestinal disorders Gastrointestinal haemorrhage	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.0% 2/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Gastrointestinal disorders Haematemesis	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Gastrointestinal disorders Ileus	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Gastrointestinal disorders Large intestinal obstruction	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 1/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Gastrointestinal disorders Lower gastrointestinal haemorrhage	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Gastrointestinal disorders Nausea	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.6% 2/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.0% 2/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Gastrointestinal disorders Obstruction gastric	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Gastrointestinal disorders Oesophageal haemorrhage	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Gastrointestinal disorders Proctalgia	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Gastrointestinal disorders Small intestinal obstruction	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.5% 2/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Gastrointestinal disorders Vomiting	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	8.3% 3/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
General disorders Catheter site extravasation	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
General disorders Catheter site haematoma	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
General disorders Chest pain	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
General disorders Fatigue	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
General disorders Performance status decreased	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
General disorders Pyrexia	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	13.9% 5/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.0% 2/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Hepatobiliary disorders Hepatic failure	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Hepatobiliary disorders Hyperbilirubinaemia	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Infections and infestations Abdominal abscess	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Infections and infestations Bacteraemia	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.6% 2/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Infections and infestations Cellulitis	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	8.3% 3/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 1/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Infections and infestations Cellulitis of male external genital organ	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Infections and infestations Cystitis	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Infections and infestations Escherichia pyelonephritis	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Infections and infestations Gangrene	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Infections and infestations Influenza	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Infections and infestations Large intestine infection	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Infections and infestations Peritonitis bacterial	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Infections and infestations Pneumonia	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Infections and infestations Pneumonia streptococcal	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Infections and infestations Pyelonephritis	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Infections and infestations Rotavirus infection	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Infections and infestations Sepsis	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.4% 2/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 1/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Infections and infestations Septic shock	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.0% 2/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Infections and infestations Skin infection	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Infections and infestations Urinary tract infection	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Infections and infestations Urosepsis	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Injury, poisoning and procedural complications Carbon monoxide poisoning	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Injury, poisoning and procedural complications Fall	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Injury, poisoning and procedural complications Infusion related reaction	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Injury, poisoning and procedural complications Ligament sprain	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Injury, poisoning and procedural complications Post procedural complication	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Investigations Anticoagulation drug level above therapeutic	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Metabolism and nutrition disorders Dehydration	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	8.3% 3/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Metabolism and nutrition disorders Diabetic ketoacidosis	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Metabolism and nutrition disorders Failure to thrive	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Metabolism and nutrition disorders Fluid overload	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Metabolism and nutrition disorders Hypokalaemia	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.6% 2/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Metabolism and nutrition disorders Hyponatraemia	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.0% 2/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Musculoskeletal and connective tissue disorders Flank pain	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Musculoskeletal and connective tissue disorders Muscular weakness	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Musculoskeletal and connective tissue disorders Musculoskeletal chest pain	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Musculoskeletal and connective tissue disorders Rhabdomyolysis	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Diffuse large B-cell lymphoma	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Metastases to meninges	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Nervous system disorders Cerebrovascular accident	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Nervous system disorders Haemorrhage intracranial	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Nervous system disorders Hypoaesthesia	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Nervous system disorders Transient ischaemic attack	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Nervous system disorders Tremor	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Nervous system disorders Unresponsive to stimuli	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Psychiatric disorders Anxiety	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Psychiatric disorders Confusional state	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Psychiatric disorders Mental status changes	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Renal and urinary disorders Acute kidney injury	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	16.7% 1/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.6% 2/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Renal and urinary disorders Haematuria	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Renal and urinary disorders Hydronephrosis	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Renal and urinary disorders Nephrolithiasis	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Renal and urinary disorders Urinary retention	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Renal and urinary disorders Urinary tract obstruction	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Respiratory, thoracic and mediastinal disorders Acute respiratory failure	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.4% 2/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Respiratory, thoracic and mediastinal disorders Aspiration	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Respiratory, thoracic and mediastinal disorders Chronic obstructive pulmonary disease	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	20.0% 2/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Respiratory, thoracic and mediastinal disorders Haemoptysis	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Respiratory, thoracic and mediastinal disorders Hypersensitivity pneumonitis	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Respiratory, thoracic and mediastinal disorders Hypoxia	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.6% 2/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Respiratory, thoracic and mediastinal disorders Pleural effusion	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	16.7% 1/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Respiratory, thoracic and mediastinal disorders Pneumonia aspiration	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Respiratory, thoracic and mediastinal disorders Pneumonitis	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.6% 2/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Respiratory, thoracic and mediastinal disorders Pneumothorax	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.8% 3/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Respiratory, thoracic and mediastinal disorders Pulmonary oedema	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Respiratory, thoracic and mediastinal disorders Respiratory failure	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Skin and subcutaneous tissue disorders Diabetic foot	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Skin and subcutaneous tissue disorders Rash	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Vascular disorders Deep vein thrombosis	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.5% 2/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Vascular disorders Embolism	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.6% 2/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Vascular disorders Haematoma	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Vascular disorders Shock haemorrhagic	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).

Other adverse events

Measure	Part A: ADX 200 mg n=4 participants at risk Participants with advanced solid tumors who had failed or were intolerant to standard therapy or for whom no standard therapy existed, received 200 mg ADX as monotherapy via IV infusion (approximately 30 minutes) every 2 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part A: ADX 600 mg n=3 participants at risk Participants with advanced solid tumors who had failed or were intolerant to standard therapy or for whom no standard therapy existed, received 600 mg ADX as monotherapy via IV infusion (approximately 30 minutes) every 2 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part A: ADX 1800 mg n=6 participants at risk Participants with advanced solid tumors who had failed or were intolerant to standard therapy or for whom no standard therapy existed, received 1800 mg ADX as monotherapy via IV infusion (approximately 30 minutes) every 2 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: PAC, ADX 800 mg n=36 participants at risk Participants with PAC received ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (gemcitabine and nab paclitaxel, on Days 1, 8, and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: LAC, ADX 1200 mg n=10 participants at risk Participants with LAC received ADX 1200 mg every 3 weeks via IV infusion in addition to the 21-day cycle chemotherapy (carboplatin and pemetrexed, on Day 1) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: LSC, ADX 1200 mg n=10 participants at risk Participants with LSC received ADX 1200 mg every 3 weeks via IV infusion in addition to the 21-day cycle chemotherapy (carboplatin and paclitaxel, on Day 1) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: EGC, ADX 800 mg n=40 participants at risk Participants with EGC received ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (mFOLFOX6, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: FL CRC, ADX 800 mg+BEV 5 mg/kg n=45 participants at risk Participants with CRC received FL treatment with ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (mFOLFOX6 and bevacizumab 5 mg/kg, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: FL CRC, ADX 800 mg+BEV 10 mg/kg n=11 participants at risk Participants with CRC received FL treatment with ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (mFOLFOX6 and bevacizumab 10 mg/kg, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: SL CRC, ADX 800 mg+BEV 5 mg/kg n=44 participants at risk Participants with CRC received SL treatment with ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (FOLFIRI and bevacizumab 5 mg/kg, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: SL CRC, ADX 800 mg+BEV 10 mg/kg n=8 participants at risk Participants with CRC received SL treatment with ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (FOLFIRI and bevacizumab 10 mg/kg, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.	Part B: BRCA, ADX 800 mg n=15 participants at risk Participants with BRCA received ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (paclitaxel, on Days 1, 8, and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
General disorders Temperature intolerance	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	30.0% 12/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	37.8% 17/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.5% 2/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Metabolism and nutrition disorders Hypophosphataemia	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.5% 2/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 1/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Metabolism and nutrition disorders Hypoproteinaemia	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Gastrointestinal disorders Constipation	25.0% 1/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	19.4% 7/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	40.0% 4/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	35.0% 14/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	37.8% 17/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	27.3% 3/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	27.3% 12/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	62.5% 5/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	46.7% 7/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Cardiac disorders Bradycardia	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Blood and lymphatic system disorders Anaemia	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	30.6% 11/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	70.0% 7/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	20.0% 2/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	30.0% 12/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	20.0% 9/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	25.0% 11/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	25.0% 2/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	20.0% 3/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Blood and lymphatic system disorders Hypercoagulation	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Blood and lymphatic system disorders Leukocytosis	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Blood and lymphatic system disorders Leukopenia	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Blood and lymphatic system disorders Neutropenia	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	33.3% 12/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	40.0% 4/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	20.0% 2/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	40.0% 16/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	40.0% 18/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	45.5% 5/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	27.3% 12/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	62.5% 5/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	40.0% 6/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Blood and lymphatic system disorders Pancytopenia	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	8.3% 3/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	20.0% 2/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Blood and lymphatic system disorders Thrombocytopenia	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	27.8% 10/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	30.0% 3/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	30.0% 3/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	20.0% 8/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 3/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Cardiac disorders Angina pectoris	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.0% 2/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Cardiac disorders Atrial fibrillation	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Cardiac disorders Palpitations	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	16.7% 1/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Cardiac disorders Sinus tachycardia	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.6% 2/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.0% 2/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Cardiac disorders Tachycardia	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	8.3% 3/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.4% 2/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Ear and labyrinth disorders Ear pain	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Ear and labyrinth disorders Tinnitus	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	20.0% 2/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Ear and labyrinth disorders Vertigo	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	7.5% 3/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.4% 2/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Eye disorders Conjunctival oedema	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Eye disorders Dry eye	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	20.0% 2/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Eye disorders Erythema of eyelid	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 1/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Eye disorders Eye swelling	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Eye disorders Lacrimation increased	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.6% 2/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.5% 2/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Eye disorders Ocular hyperaemia	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.0% 2/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Eye disorders Photopsia	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Eye disorders Vision blurred	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.6% 2/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.0% 2/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Gastrointestinal disorders Abdominal discomfort	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.6% 2/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.4% 2/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	25.0% 2/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Gastrointestinal disorders Abdominal distension	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.6% 2/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 4/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	8.9% 4/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.5% 2/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Gastrointestinal disorders Abdominal pain	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	16.7% 1/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	16.7% 6/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	20.0% 2/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 5/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	26.7% 12/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	25.0% 11/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	62.5% 5/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	20.0% 3/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Gastrointestinal disorders Abdominal pain upper	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.6% 2/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 4/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	11.1% 5/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.8% 3/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 1/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Gastrointestinal disorders Abdominal wall haematoma	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Gastrointestinal disorders Anorectal discomfort	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.5% 2/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 1/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Gastrointestinal disorders Ascites	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Gastrointestinal disorders Colitis	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 1/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Gastrointestinal disorders Dental caries	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Gastrointestinal disorders Diarrhoea	50.0% 2/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	44.4% 16/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	40.0% 4/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	20.0% 2/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	47.5% 19/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	55.6% 25/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	27.3% 3/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	63.6% 28/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	75.0% 6/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	33.3% 5/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Gastrointestinal disorders Dry mouth	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.6% 2/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	15.0% 6/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	8.9% 4/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Gastrointestinal disorders Dyschezia	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 1/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Gastrointestinal disorders Dyspepsia	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	8.3% 3/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 4/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	11.1% 5/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	18.2% 2/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 1/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Gastrointestinal disorders Dysphagia	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 5/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 3/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Gastrointestinal disorders Erosive oesophagitis	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
General disorders Swelling	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Gastrointestinal disorders Flatulence	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.0% 2/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Gastrointestinal disorders Gastrointestinal haemorrhage	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 1/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Gastrointestinal disorders Gastrooesophageal reflux disease	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.0% 2/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.4% 2/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.5% 2/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	25.0% 2/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Gastrointestinal disorders Gingival bleeding	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.8% 3/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Gastrointestinal disorders Haematochezia	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.4% 2/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 4/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 1/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Gastrointestinal disorders Haemorrhoidal haemorrhage	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 1/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Gastrointestinal disorders Haemorrhoids	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.6% 2/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.4% 2/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 4/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 1/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Gastrointestinal disorders Mouth ulceration	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.8% 3/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Gastrointestinal disorders Nausea	25.0% 1/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	66.7% 2/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	33.3% 2/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	50.0% 18/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	30.0% 3/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	50.0% 5/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	62.5% 25/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	73.3% 33/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	81.8% 9/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	61.4% 27/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	62.5% 5/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	40.0% 6/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Gastrointestinal disorders Oral pain	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.6% 2/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.0% 2/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.4% 2/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.8% 3/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Gastrointestinal disorders Proctalgia	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	13.6% 6/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 1/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Gastrointestinal disorders Rectal fissure	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 1/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Gastrointestinal disorders Rectal haemorrhage	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	8.9% 4/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.5% 2/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Gastrointestinal disorders Stomatitis	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	20.0% 2/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	17.5% 7/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	24.4% 11/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	34.1% 15/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	50.0% 4/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Gastrointestinal disorders Toothache	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Gastrointestinal disorders Vomiting	25.0% 1/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	33.3% 2/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	25.0% 9/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	20.0% 2/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	32.5% 13/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	31.1% 14/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	45.5% 5/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	31.8% 14/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	37.5% 3/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	13.3% 2/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
General disorders Asthenia	25.0% 1/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	33.3% 1/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	16.7% 6/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 4/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	17.8% 8/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	18.2% 2/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	13.6% 6/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	62.5% 5/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
General disorders Axillary pain	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
General disorders Catheter site pain	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
General disorders Chest discomfort	25.0% 1/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	16.7% 1/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.4% 2/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
General disorders Chest pain	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.0% 2/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	11.1% 5/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
General disorders Chills	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.6% 2/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.0% 2/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.4% 2/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.5% 2/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 1/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
General disorders Complication associated with device	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
General disorders Early satiety	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.0% 2/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
General disorders Fatigue	50.0% 2/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	66.7% 2/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	75.0% 27/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	50.0% 5/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	70.0% 7/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	57.5% 23/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	80.0% 36/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	63.6% 7/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	59.1% 26/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	75.0% 6/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	73.3% 11/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
General disorders Gait disturbance	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.6% 2/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	7.5% 3/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	8.9% 4/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
General disorders Generalised oedema	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.6% 2/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
General disorders Influenza like illness	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	8.3% 3/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 1/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
General disorders Malaise	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.0% 2/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
General disorders Mucosal inflammation	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 5/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	17.8% 8/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	20.5% 9/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
General disorders Non-cardiac chest pain	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.8% 3/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 1/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
General disorders Oedema peripheral	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	55.6% 20/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	20.0% 2/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	27.5% 11/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	11.1% 5/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 4/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	13.3% 2/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
General disorders Pain	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	13.9% 5/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.4% 2/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
General disorders Peripheral swelling	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.4% 2/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.5% 2/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 1/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
General disorders Pyrexia	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	22.2% 8/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	15.0% 6/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.4% 2/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	18.2% 8/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	25.0% 2/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Hepatobiliary disorders Cholecystitis	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Hepatobiliary disorders Hepatic cirrhosis	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Immune system disorders Drug hypersensitivity	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 3/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Immune system disorders Hypersensitivity	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Immune system disorders Seasonal allergy	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Infections and infestations Abscess	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	33.3% 1/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Infections and infestations Bacteraemia	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Infections and infestations Candida infection	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	8.3% 3/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.8% 3/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Infections and infestations Cellulitis	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	33.3% 1/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	11.1% 4/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	18.2% 2/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Infections and infestations Cystitis	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Infections and infestations Ear infection	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 1/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Infections and infestations Eye infection	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.6% 2/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Infections and infestations Gastroenteritis	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Infections and infestations Gastrointestinal infection	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Infections and infestations Hepatitis C	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Infections and infestations Herpes zoster	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Infections and infestations Hordeolum	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.6% 2/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Infections and infestations Infected cyst	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Injury, poisoning and procedural complications Gastrointestinal stoma complication	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Infections and infestations Laryngitis	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Infections and infestations Lung infection	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 1/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Infections and infestations Nail infection	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Infections and infestations Nasopharyngitis	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.8% 3/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 1/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Infections and infestations Oral candidiasis	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Infections and infestations Pneumonia	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.0% 2/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.5% 2/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	13.3% 2/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Infections and infestations Pyuria	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Infections and infestations Sinusitis	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	7.5% 3/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Infections and infestations Upper respiratory tract infection	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	16.7% 1/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	8.3% 3/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 5/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 3/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	27.3% 3/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.8% 3/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Infections and infestations Urinary tract infection	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	11.1% 4/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	7.5% 3/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	13.3% 6/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	18.2% 8/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	25.0% 2/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Infections and infestations Wound infection	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Injury, poisoning and procedural complications Arthropod bite	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 1/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Injury, poisoning and procedural complications Contusion	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	7.5% 3/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.4% 2/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Injury, poisoning and procedural complications Fall	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	8.3% 3/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 5/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	15.6% 7/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	13.6% 6/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Injury, poisoning and procedural complications Infusion related reaction	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	11.1% 5/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 4/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 1/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	13.3% 2/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Injury, poisoning and procedural complications Injection related reaction	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Injury, poisoning and procedural complications Limb injury	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 1/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Injury, poisoning and procedural complications Procedural pain	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Injury, poisoning and procedural complications Skin abrasion	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Injury, poisoning and procedural complications Skin laceration	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	7.5% 3/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.5% 2/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 1/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Injury, poisoning and procedural complications Stoma complication	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Injury, poisoning and procedural complications Wound dehiscence	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.6% 2/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Investigations Activated partial thromboplastin time prolonged	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.0% 2/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Investigations Alanine aminotransferase increased	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	8.9% 4/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 4/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	20.0% 3/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Investigations Aspartate aminotransferase increased	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	33.3% 1/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.0% 2/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	13.3% 6/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.8% 3/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 1/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	20.0% 3/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Investigations Blood alkaline phosphatase increased	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	7.5% 3/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 1/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Investigations Blood bilirubin increased	25.0% 1/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Investigations Blood creatinine increased	25.0% 1/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.8% 3/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Investigations Blood thyroid stimulating hormone increased	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 1/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Investigations Carcinoembryonic antigen increased	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.0% 2/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Investigations Haemoglobin decreased	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Investigations Heart rate irregular	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Investigations International normalised ratio increased	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.0% 2/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 3/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Investigations Liver function test increased	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Investigations Lymphocyte count decreased	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.0% 2/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Investigations Neutrophil count decreased	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	16.7% 6/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	17.5% 7/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	22.2% 10/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	18.2% 2/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	20.5% 9/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Investigations Platelet count decreased	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	11.1% 4/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	17.5% 7/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	11.1% 5/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	11.4% 5/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 1/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	13.3% 2/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Investigations Prothrombin time prolonged	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.0% 2/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Investigations Weight decreased	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	19.4% 7/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 5/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	15.6% 7/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 1/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Investigations Weight increased	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.4% 2/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 1/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Investigations White blood cell count decreased	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.6% 2/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 5/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	11.1% 5/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	13.6% 6/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Metabolism and nutrition disorders Decreased appetite	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	16.7% 1/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	27.8% 10/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	20.0% 2/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	30.0% 12/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	42.2% 19/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	27.3% 3/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	20.5% 9/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	25.0% 2/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	20.0% 3/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Metabolism and nutrition disorders Dehydration	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.6% 2/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	17.5% 7/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	26.7% 12/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	18.2% 2/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	20.5% 9/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 1/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	26.7% 4/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Metabolism and nutrition disorders Fluid overload	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Metabolism and nutrition disorders Folate deficiency	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Metabolism and nutrition disorders Hypercalcaemia	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Metabolism and nutrition disorders Hyperglycaemia	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	11.1% 4/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.0% 2/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Metabolism and nutrition disorders Hyperkalaemia	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Metabolism and nutrition disorders Hypoalbuminaemia	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.6% 2/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.0% 2/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Metabolism and nutrition disorders Hypocalcaemia	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.5% 2/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 1/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Metabolism and nutrition disorders Hypoglycaemia	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 1/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Metabolism and nutrition disorders Hypokalaemia	25.0% 1/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	22.2% 8/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 4/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	20.0% 9/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	27.3% 3/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	18.2% 8/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	50.0% 4/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Metabolism and nutrition disorders Hypomagnesaemia	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	8.3% 3/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 3/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	11.4% 5/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	25.0% 2/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Metabolism and nutrition disorders Hyponatraemia	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	8.3% 3/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	7.5% 3/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.4% 2/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Metabolism and nutrition disorders Malnutrition	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.0% 2/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.4% 2/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Musculoskeletal and connective tissue disorders Arthralgia	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	33.3% 1/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	16.7% 1/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	30.0% 3/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	15.0% 6/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	22.2% 10/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	18.2% 8/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	20.0% 3/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.6% 2/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	17.5% 7/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	20.0% 9/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.8% 3/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	25.0% 2/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Musculoskeletal and connective tissue disorders Bone pain	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.0% 2/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.5% 2/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Musculoskeletal and connective tissue disorders Flank pain	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.5% 2/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Musculoskeletal and connective tissue disorders Joint stiffness	25.0% 1/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Musculoskeletal and connective tissue disorders Muscle spasms	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.4% 2/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.8% 3/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Musculoskeletal and connective tissue disorders Muscular weakness	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	16.7% 1/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	8.3% 3/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 4/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 3/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 4/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Musculoskeletal and connective tissue disorders Musculoskeletal chest pain	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.6% 2/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.4% 2/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	13.3% 2/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Musculoskeletal and connective tissue disorders Musculoskeletal pain	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	16.7% 1/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 4/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	17.8% 8/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 4/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Musculoskeletal and connective tissue disorders Myalgia	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	19.4% 7/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	30.0% 3/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.0% 2/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 3/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	11.4% 5/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Musculoskeletal and connective tissue disorders Pain in extremity	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	22.2% 8/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 5/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	8.9% 4/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 4/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	25.0% 2/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Musculoskeletal and connective tissue disorders Pain in jaw	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.0% 2/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 3/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Musculoskeletal and connective tissue disorders Pathological fracture	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Musculoskeletal and connective tissue disorders Spondylitis	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Cardiac myxoma	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Intracranial tumour haemorrhage	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	16.7% 1/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Nervous system disorders Tremor	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Nervous system disorders Amnesia	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	33.3% 1/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Nervous system disorders Ataxia	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Nervous system disorders Balance disorder	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.6% 2/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Nervous system disorders Dizziness	25.0% 1/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	33.3% 1/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	16.7% 1/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	19.4% 7/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	20.0% 2/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	20.0% 2/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	15.0% 6/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	15.6% 7/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	18.2% 2/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	25.0% 11/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	25.0% 2/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Nervous system disorders Dysaesthesia	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	7.5% 3/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	27.3% 3/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Nervous system disorders Dysgeusia	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	27.8% 10/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	20.0% 8/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	13.3% 6/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	18.2% 2/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.5% 2/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	20.0% 3/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Nervous system disorders Facial paralysis	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	16.7% 1/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Nervous system disorders Headache	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	13.9% 5/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	15.0% 6/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	28.9% 13/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	18.2% 8/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 1/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	13.3% 2/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Nervous system disorders Hypoaesthesia	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.0% 2/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.4% 2/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Nervous system disorders Loss of consciousness	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Nervous system disorders Memory impairment	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 3/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Nervous system disorders Movement disorder	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 1/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Nervous system disorders Neuralgia	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.6% 2/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Nervous system disorders Neuropathy peripheral	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	33.3% 1/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	30.6% 11/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	40.0% 4/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	47.5% 19/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	35.6% 16/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	36.4% 4/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 4/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 1/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	33.3% 5/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Nervous system disorders Paraesthesia	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	22.2% 8/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	22.5% 9/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	35.6% 16/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.5% 2/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 1/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Nervous system disorders Peripheral sensory neuropathy	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 4/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	48.9% 22/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	27.3% 3/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 4/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	13.3% 2/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Nervous system disorders Presyncope	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.5% 2/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 1/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Nervous system disorders Sciatica	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Nervous system disorders Seizure	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Nervous system disorders Somnolence	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Nervous system disorders Syncope	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	8.9% 4/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Nervous system disorders Taste disorder	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.0% 2/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	11.1% 5/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Nervous system disorders Toxic encephalopathy	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Nervous system disorders Vocal cord paralysis	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Psychiatric disorders Agitation	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.0% 2/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Psychiatric disorders Anxiety	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	16.7% 6/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 5/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 3/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.8% 3/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	13.3% 2/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Psychiatric disorders Confusional state	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.4% 2/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Psychiatric disorders Delirium	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 1/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Psychiatric disorders Depression	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	11.1% 4/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	15.0% 6/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	8.9% 4/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.5% 2/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	37.5% 3/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Psychiatric disorders Insomnia	25.0% 1/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	8.3% 3/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	20.0% 2/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	25.0% 10/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	17.8% 8/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	18.2% 2/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.5% 2/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	13.3% 2/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Renal and urinary disorders Dysuria	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.6% 2/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	11.1% 5/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Renal and urinary disorders Haematuria	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.6% 2/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	7.5% 3/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	8.9% 4/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	11.4% 5/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Renal and urinary disorders Nephrolithiasis	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Renal and urinary disorders Pollakiuria	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.4% 2/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Renal and urinary disorders Proteinuria	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	24.4% 11/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	11.4% 5/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Renal and urinary disorders Ureterolithiasis	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Renal and urinary disorders Urinary incontinence	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.6% 2/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.4% 2/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Renal and urinary disorders Urinary retention	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	8.3% 3/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Respiratory, thoracic and mediastinal disorders Chronic obstructive pulmonary disease	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Respiratory, thoracic and mediastinal disorders Cough	25.0% 1/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	33.3% 2/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	30.6% 11/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	20.0% 2/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	15.0% 6/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	20.0% 9/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	13.6% 6/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	26.7% 4/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Respiratory, thoracic and mediastinal disorders Dysphonia	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	30.0% 3/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 4/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.4% 2/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Respiratory, thoracic and mediastinal disorders Dyspnoea	25.0% 1/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	50.0% 3/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	19.4% 7/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	20.0% 2/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	20.0% 2/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	15.0% 6/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	26.7% 12/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	11.4% 5/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 1/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	33.3% 5/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Respiratory, thoracic and mediastinal disorders Dyspnoea exertional	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.0% 2/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.4% 2/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.5% 2/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	20.0% 3/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Respiratory, thoracic and mediastinal disorders Emphysema	25.0% 1/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Respiratory, thoracic and mediastinal disorders Epistaxis	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	11.1% 4/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	20.0% 2/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 4/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	15.6% 7/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	18.2% 2/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	20.5% 9/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 1/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	13.3% 2/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Respiratory, thoracic and mediastinal disorders Haemoptysis	25.0% 1/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	20.0% 2/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	30.0% 3/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Respiratory, thoracic and mediastinal disorders Hiccups	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	8.3% 3/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	13.3% 6/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Respiratory, thoracic and mediastinal disorders Hypoxia	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.0% 2/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.4% 2/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Respiratory, thoracic and mediastinal disorders Lower respiratory tract congestion	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.0% 2/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Respiratory, thoracic and mediastinal disorders Nasal congestion	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	8.3% 3/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.0% 2/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 4/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Respiratory, thoracic and mediastinal disorders Nasal dryness	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.4% 2/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Respiratory, thoracic and mediastinal disorders Organising pneumonia	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.6% 2/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.0% 2/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	13.3% 6/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.5% 2/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	25.0% 2/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Respiratory, thoracic and mediastinal disorders Paranasal sinus hypersecretion	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	8.9% 4/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 1/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Respiratory, thoracic and mediastinal disorders Pleural effusion	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Respiratory, thoracic and mediastinal disorders Pleuritic pain	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Respiratory, thoracic and mediastinal disorders Productive cough	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.4% 2/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.5% 2/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 1/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	8.9% 4/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	13.3% 2/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Skin and subcutaneous tissue disorders Erythema	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.5% 2/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 1/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Respiratory, thoracic and mediastinal disorders Rhinitis allergic	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.4% 2/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Respiratory, thoracic and mediastinal disorders Rhinorrhoea	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.0% 2/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	8.9% 4/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.5% 2/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Respiratory, thoracic and mediastinal disorders Sinus congestion	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	16.7% 1/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.0% 2/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Respiratory, thoracic and mediastinal disorders Sputum discoloured	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Respiratory, thoracic and mediastinal disorders Throat irritation	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Respiratory, thoracic and mediastinal disorders Throat tightness	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Skin and subcutaneous tissue disorders Alopecia	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	55.6% 20/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	20.0% 2/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	50.0% 5/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 4/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	11.1% 5/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	34.1% 15/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	25.0% 2/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	60.0% 9/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Skin and subcutaneous tissue disorders Dermatitis acneiform	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 3/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Skin and subcutaneous tissue disorders Dry skin	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	22.2% 8/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.0% 2/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	11.1% 5/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.5% 2/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Skin and subcutaneous tissue disorders Granuloma annulare	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Skin and subcutaneous tissue disorders Hyperhidrosis	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	8.9% 4/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.5% 2/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Skin and subcutaneous tissue disorders Nail discolouration	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Skin and subcutaneous tissue disorders Nail ridging	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Skin and subcutaneous tissue disorders Night sweats	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	16.7% 1/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 3/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Skin and subcutaneous tissue disorders Palmar-plantar erythrodysaesthesia syndrome	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.0% 2/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 3/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	18.2% 2/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 4/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Skin and subcutaneous tissue disorders Pruritus	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	8.3% 3/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	15.0% 6/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.4% 2/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.5% 2/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 1/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Skin and subcutaneous tissue disorders Rash	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	25.0% 9/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	20.0% 2/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	20.0% 8/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 3/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.5% 2/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 1/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Skin and subcutaneous tissue disorders Rash generalised	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	8.3% 3/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Skin and subcutaneous tissue disorders Rash macular	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 1/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Skin and subcutaneous tissue disorders Rash maculo-papular	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	8.3% 3/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.5% 1/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.8% 3/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	12.5% 1/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Skin and subcutaneous tissue disorders Skin discolouration	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.4% 2/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	18.2% 2/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Skin and subcutaneous tissue disorders Skin lesion	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.8% 1/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Skin and subcutaneous tissue disorders Skin ulcer	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.0% 2/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 3/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.8% 3/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Skin and subcutaneous tissue disorders Urticaria	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.0% 2/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Vascular disorders Aortic intramural haematoma	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Vascular disorders Deep vein thrombosis	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	13.9% 5/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.4% 2/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.3% 1/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Vascular disorders Embolism	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.5% 2/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Vascular disorders Flushing	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	8.3% 3/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.5% 2/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.7% 1/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Vascular disorders Haematoma	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	2.2% 1/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Vascular disorders Hot flush	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.0% 2/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	6.8% 3/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Vascular disorders Hypertension	25.0% 1/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	8.3% 3/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.0% 2/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	40.0% 18/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	18.2% 2/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	11.4% 5/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Vascular disorders Hypotension	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	11.1% 4/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	20.0% 2/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	5.0% 2/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	4.4% 2/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 1/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	9.1% 4/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
Vascular disorders Peripheral coldness	0.00% 0/4 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/3 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/6 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/36 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	10.0% 1/10 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/40 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/45 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/11 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/44 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/8 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).	0.00% 0/15 • Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month) The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).

Additional Information

Gilead Clinical Study Information Center

Gilead Sciences

Phone: 1-833-445-3230 (GILEAD-0)

Email: GileadClinicalTrials@gilead.com

Results disclosure agreements

• Principal investigator is a sponsor employee After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met: * The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or * The study has been completed at all study sites for at least 2 years
• Publication restrictions are in place

Restriction type: OTHER